Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Ralzapastotug · AB-308

Monoclonal antibody · Inhibitor of T-cell immunoreceptor with Ig and ITIM domains (TIGIT) · developed by Arcus Biosciences

Phase 1 Most advanced trial (none active)
RCUS Developer
1 Registered trials

What is Ralzapastotug?

Ralzapastotug is an IgG1 monoclonal antibody that binds TIGIT, an immune inhibitory receptor on tumor-infiltrating lymphocytes. By blocking TIGIT's interaction with CD112 and CD155, it allows these ligands to engage the costimulatory receptor CD226, promoting T-cell-mediated immune responses. It is being studied in multiple solid tumors and hematologic malignancies.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
AB-308
Drug type
Monoclonal antibody
Targets
T-cell immunoreceptor with Ig and ITIM domains (TIGIT), CD112 (nectin-2) (NECTIN2) (binding partner it blocks), CD155 (poliovirus receptor) (PVR) (binding partner it blocks)
Mechanism
Inhibitor of T-cell immunoreceptor with Ig and ITIM domains (TIGIT)
Pathways
CD226 (DNAM-1) signaling, T-cell activation, NK cell activation
Therapy area
Oncology
Developer
Arcus Biosciences, Inc. (RCUS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
J95TV367TU

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04772989 Phase 1 Advanced Solid Tumor Completed RCUS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorCervical CancerDiffuse Large B Cell Lymphoma (DLBCL)Esophageal CancerGastric CancerGastroesophageal Junction AdenocarcinomaLymphoma, Non-HodgkinMelanomaMultiple MyelomaNon Small Cell Lung Cancer (NSCLC)

Other drugs acting on TIGIT

More from Arcus Biosciences

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the RCUS page.

Follow RCUS, the company behind Ralzapastotug

See RCUS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RCUS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.